Sign in Subscribe
Diseases

Psychosis in Parkinson's and Alzheimer's Disease Market to Experience Significant Growth by 2034

Strategic Insights

— 2 min read

The number of patients diagnosed with Parkinson's disease in the 7MM reached 2.6 million in 2023, with the United States accounting for approximately 45% of these cases, while the EU4 (France, Germany, Italy, and Spain) and the UK together represented roughly 45%, and Japan contributed around 10%. The prevalence of Parkinson's disease is projected to rise by 2034. Additionally, an estimated 6.9 million diagnosed cases of psychosis associated with Parkinson's and Alzheimer's disease were reported in the 7MM in 2023.

Key Takeaways:

  • The psychosis in Parkinson's disease and Alzheimer's disease market in the 7MM was valued at approximately USD 1,290 million in 2023 and is projected to grow over the forecast period from 2024 to 2034.
  • Emerging therapies such as NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others are expected to drive significant growth in the market in the coming years.
  • Key companies actively developing therapies for psychosis in Parkinson's and Alzheimer's disease include Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others.
  • Promising pipeline candidates include Ulotaront (SEP-363856), KarXT (xanomeline-trospium), and ITI-1284.
  • The FDA approved Rexulti (brexpiprazole) in May 2023 for treating agitation associated with dementia due to Alzheimer's disease.
  • The market for psychosis in these neurodegenerative diseases is expected to expand, driven by the launch of innovative therapies.
  • With the aging population growing, the prevalence of Parkinson's and Alzheimer's disease is expected to increase, fueling demand for effective psychosis treatments.
  • Greater awareness of psychosis as a significant symptom may lead to earlier diagnosis and better management, further supporting market growth.
  • However, substantial unmet needs remain due to the lack of curative therapies and reliable biomarkers, making early diagnosis and treatment challenging.

Statistics:

  • 2.6 million patients diagnosed with Parkinson's disease in the 7MM in 2023.
  • 6.9 million diagnosed cases of psychosis associated with Parkinson's and Alzheimer's disease reported in the 7MM in 2023.
  • 45% of Parkinson's disease cases in the 7MM were reported in the United States.
  • 45% of Parkinson's disease cases in the 7MM were reported in the EU4 and the UK.
  • 10% of Parkinson's disease cases in the 7MM were reported in Japan.
  • The market for psychosis in Parkinson's and Alzheimer's disease is expected to grow to USD 1,290 million by 2034.
  • The number of patients diagnosed with psychosis associated with Parkinson's and Alzheimer's disease is projected to increase by 2034.

Sources:

  • DelveInsight's analysis of the psychosis in Parkinson's disease and Alzheimer's disease market in the 7MM.
  • National Institute of Mental Health (NIMH) for information on psychosis.
  • Acadia Pharmaceuticals for information on NUPLAZID (pimavanserin).
  • Sunovion Pharmaceuticals for information on Ulotaront (SEP-363856).
  • Karuna Therapeutics for information on KarXT (xanomeline-trospium).
  • Intra-Cellular Therapies for information on ITI-1284.
  • FDA approval of Rexulti (brexpiprazole) for treating agitation associated with dementia due to Alzheimer's disease.
  • DelveInsight's report on "Psychosis in Parkinson's and Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast-2034".

Read more